COVID-19 Vaccine Doses: Who’s Got At Least One?
With COVID-19 vaccine rollouts well underway in some countries, a return to ‘normal life’ could come sooner than later.
That said, many jurisdictions have experienced serious delays and supply shortages that have made it difficult to distribute COVID-19 vaccine doses to their populations. As of mid-February, 130 countries had not been able to begin vaccinating at all.
This interactive chart from Our World in Data tracks the share of people in each country that have received COVID-19 vaccine doses so far.
The Global Vaccine Rollout
As of publication date, roughly 100 countries have begun vaccine distribution, with about seven different vaccines available for public use at this stage.
The sheer logistical challenge of doling out vaccines is immense. Experts estimate that 70-80% of the world’s population will need to be vaccinated to reach herd immunity. Additionally, some of the vaccines require two doses which adds extra time and complexity to the process.
Here’s how the various vaccines compare in terms of required doses and levels of effectiveness.
|Vaccine||Number of Shots Required||Effectiveness|
|Johnson & Johnson||1||66%|
|Novavax (*Novavax has not yet been approved for public use)||2||89%|
Source: Bloomberg Vaccine Tracker
One key barrier to successfully administering vaccines is the prevalence of vaccine hesitancy around the globe.
For example, many people in Germany have been refusing the AstraZeneca vaccine due to a belief in its ineffectiveness and a preference for the ‘in-house’ German Pfizer/BioNTech vaccine. Although 1.45 million AstraZeneca COVID-19 vaccine doses have arrived in the country so far, just 270,000 have been administered.
Who’s Got at Least One Dose?
According to Bloomberg’s Vaccine Tracker, the current rate of doses being administered globally is more than 6 million per day. In particular, the U.S. has been remarkably efficient at administering doses, with a vaccine administration rate of over 1.7 million per day.
Here’s a breakdown of the countries who have begun vaccinating their populations and their current daily rate of doses administered.
|Country||Daily Rate of Doses Administered|
|🇰🇾 Cayman Islands||621|
|🇨🇷 Costa Rica||706|
|🇨🇿 Czech Republic||15,298|
|🇩🇴 Dominican Republic||9,356|
|🇮🇲 Isle of Man||599|
|🇸🇦 Saudi Arabia||34,180|
|🇿🇦 South Africa||7,569|
|🇱🇰 Sri Lanka||4,755|
Source: Bloomberg Vaccine Tracker. Data as of Feb 28, 2021.
Certain countries appear to be on track to distribute all of their COVID-19 vaccine doses at an immensely quick rate. For example, the UK plans to vaccinate enough people to be able to lift all lockdown restrictions completely by the end of June 2021.
Additionally, the first COVAX rollouts have officially begun; COVAX is an initiative working to ensure equitable access to COVID-19 vaccines. Ghana was the first country to receive doses through the initiative.
Back to Normal?
Most countries are prioritizing vaccinating their high-risk groups first, from older adults to healthcare workers. That said, the planning required to vaccinate an entire population needs to be carefully thought out and often comes with immense logistical challenges.
While many countries have begun to immunize their populations, others have not been able to purchase doses yet. At the current pace, it could take a few years before things are completely back to normal and we reach herd immunity globally.
Support the Future of Data Storytelling
Sorry to interrupt your reading, but we have a favor to ask. At Visual Capitalist we believe in a world where data can be understood by everyone. That’s why we want to build the VC App - the first app of its kind combining verifiable and transparent data with beautiful, memorable visuals. All available for free.
As a small, independent media company we don’t have the expertise in-house or the funds to build an app like this. So we’re asking our community to help us raise funds on Kickstarter.
Explainer: What to Know About Monkeypox
What is monkeypox, and what risk does it pose to the public? This infographic breaks down the symptoms, transmission, and more.
Explainer: What to Know About Monkeypox
The COVID-19 pandemic is still fresh in the minds of the people around the world, so it comes as no surprise that recent outbreaks of another virus are grabbing headlines.
Monkeypox outbreaks have now been reported in multiple countries, and it has scientists paying close attention. For everyone else, numerous questions come to the surface:
- How serious is this virus?
- How contagious is it?
- Could monkeypox develop into a new pandemic?
Below, we answer these questions and more.
What is Monkeypox?
Monkeypox is a virus in the Orthopoxvirus genus which also includes the variola virus (which causes smallpox) and the cowpox virus. The primary symptoms include fever, swollen lymph nodes, and a distinctive bumpy rash.
There are two major strains of the virus that pose very different risks:
- Congo Basin strain: 1 in 10 people infected with this strain have died
- West African strain: Approximately 1 in 100 people infected with this strain died
At the moment, health authorities in the UK have indicated they’re seeing the milder strain in patients there.
Where did Monkeypox Originate From?
The virus was originally discovered in the Democratic Republic of Congo in monkeys kept for research purposes (hence the name). Eventually, the virus made the jump to humans more than a decade after its discovery in 1958.
It is widely assumed that vaccination against another similar virus, smallpox, helped keep monkeypox outbreaks from occurring in human populations. Ironically, the successful eradication of smallpox, and eventual winding down of that vaccine program, has opened the door to a new viral threat. There is now a growing population of people who no longer have immunity against the virus.
Now that travel restrictions are lifting in many parts of the world, viruses are now able to hop between nations again. As of the publishing of this article, a handful of cases have now been reported in the U.S., Canada, the UK, and a number of European countries.
On the upside, contact tracing has helped authorities piece together the transmission of the virus. While cases are rare in Europe and North America, it is considered endemic in parts of West Africa. For example, the World Health Organization reports that Nigeria has experienced over 550 reported monkeypox cases from 2017 to today. The current UK outbreak originated from an individual who returned from a trip to Nigeria.
Could Monkeypox become a new pandemic?
Monkeypox, which primarily spreads through animal-to-human interaction, is not known to spread easily between humans. Most individuals infected with monkeypox pass the virus to between zero and one person, so outbreaks typically fizzle out. For this reason, the fact that outbreaks are occurring in several countries simultaneously is concerning for health authorities and organizations that monitor viral transmission. Experts are entertaining the possibility that the virus’ rate of transmission has increased.
Images of people covered in monkeypox lesions are shocking, and people are understandably concerned by this virus, but the good news is that members of the general public have little to fear at this stage.
I think the risk to the general public at this point, from the information we have, is very, very low.
–Tom Inglesby, Director, Johns Hopkins Center for Health Security
» For up-to-date information on monkeypox cases, check out Global.Health’s tracking spreadsheet
Visualizing How COVID-19 Antiviral Pills and Vaccines Work at the Cellular Level
Despite tackling the same disease, vaccines and antiviral pills work differently to combat COVID-19. We visualize how they work in the body.
Current Strategies to Tackle COVID-19
Since the pandemic started in 2020, a number of therapies have been developed to combat COVID-19.
The leading options for preventing infection include social distancing, mask-wearing, and vaccination. They are still recommended during the upsurge of the coronavirus’s latest mutation, the Omicron variant.
But in December 2021, The United States Food and Drug Administration (USDA) granted Emergency Use Authorization to two experimental pills for the treatment of new COVID-19 cases.
These medications, one made by Pfizer and the other by Merck & Co., hope to contribute to the fight against the coronavirus and its variants. Alongside vaccinations, they may help to curb extreme cases of COVID-19 by reducing the need for hospitalization.
Despite tackling the same disease, vaccines and pills work differently:
|Taken by injection||Taken by mouth|
|Used for prevention||Used for treatment only|
|Create an enhanced immune system by stimulating antibody production||Disrupt the assembly of new viral particles|
How a Vaccine Helps Prevent COVID-19
The main purpose of a vaccine is to prewarn the body of a potential COVID-19 infection by creating antibodies that target and destroy the coronavirus.
In order to do this, the immune system needs an antigen.
It’s difficult to do this risk-free since all antigens exist directly on a virus. Luckily, vaccines safely expose antigens to our immune systems without the dangerous parts of the virus.
In the case of COVID-19, the coronavirus’s antigen is the spike protein that covers its outer surface. Vaccines inject antigen-building instructions* and use our own cellular machinery to build the coronavirus antigen from scratch.
When exposed to the spike protein, the immune system begins to assemble antigen-specific antibodies. These antibodies wait for the opportunity to attack the real spike protein when a coronavirus enters the body. Since antibodies decrease over time, booster immunizations help to maintain a strong line of defense.
*While different vaccine technologies exist, they all do a similar thing: introduce an antigen and build a stronger immune system.
How COVID Antiviral Pills Work
Antiviral pills, unlike vaccines, are not a preventative strategy. Instead, they treat an infected individual experiencing symptoms from the virus.
These medications disrupt specific processes in the viral assembly line to choke the virus’s ability to replicate.
The Mechanism of Molnupiravir
RNA-dependent RNA Polymerase (RdRp) is a cellular component that works similar to a photocopying machine for the virus’s genetic instructions. An infected host cell is forced to produce RdRp, which starts generating more copies of the virus’s RNA.
Molnupiravir, developed by Merck & Co., is a polymerase inhibitor. It inserts itself into the viral instructions that RdRp is copying, jumbling the contents. The RdRp then produces junk.
The Mechanism of Nirmatrelvir + Ritonavir
A replicating virus makes proteins necessary for its survival in a large, clumped mass called a polyprotein. A cellular component called a protease cuts a virus’s polyprotein into smaller, workable pieces.
Pfizer’s antiviral medication is a protease inhibitor made of two pills:
- The first pill, nirmatrelvir, stops protease from cutting viral products into smaller pieces.
- The second pill, ritonavir, protects nirmatrelvir from destruction by the body and allows it to keep working.
With a faulty polymerase or a large, unusable polyprotein, antiviral medications make it difficult for the coronavirus to replicate. If treated early enough, they can lessen the virus’s impact on the body.
The Future of COVID Antiviral Pills and Medications
Antiviral medications seem to have a bright future ahead of them.
COVID-19 antivirals are based on early research done on coronaviruses from the 2002-04 SARS-CoV and the 2012 MERS-CoV outbreaks. Current breakthroughs in this technology may pave the way for better pharmaceuticals in the future.
One half of Pfizer’s medication, ritonavir, currently treats many other viruses including HIV/AIDS.
Gilead Science is currently developing oral derivatives of remdesivir, another polymerase inhibitor currently only offered to inpatients in the United States.
More coronavirus antivirals are currently in the pipeline, offering a glimpse of control on the looming presence of COVID-19.
Author’s Note: The medical information in this article is an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. Please talk to your doctor before undergoing any treatment for COVID-19. If you become sick and believe you may have symptoms of COVID-19, please follow the CDC guidelines.
Money2 weeks ago
Mapping the Migration of the World’s Millionaires
Markets2 weeks ago
Visualizing the Coming Shift in Global Economic Power (2006-2036p)
Datastream3 weeks ago
Ranked: These Are 10 of the World’s Least Affordable Housing Markets
Demographics2 weeks ago
Mapped: A Decade of Population Growth and Decline in U.S. Counties
Misc3 weeks ago
Visualizing Well-Known Airlines by Fleet Composition
Misc2 weeks ago
Iconic Infographic Map Compares the World’s Mountains and Rivers
Energy2 days ago
Who’s Still Buying Fossil Fuels From Russia?
Markets6 days ago
Interest Rate Hikes vs. Inflation Rate, by Country